Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|21|3007-3018

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.21, 2012-05, pp. : 3007-3018

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Idarucizumab: What Should We Know?

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 81-88

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?

By Nosten F.  

CNS Drugs, Vol. 11, Iss. 1, 1999-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

What do we know about the entry of Neisseria meningitidis into the meninges?

By Nassif X.   Pujol C.   Tinsley C.   Morand P.   Eugene E.   Marceau M.   Perrin A.   Pron B.   Taha M.-K.  

European Journal of Medicinal Chemistry, Vol. 95, Iss. 4, 1997-10 ,pp. : 219-235

Elsevier

Access to resources Recommend Favorite

ACE Inhibitors in Heart Failure: What More Do We Need to Know?

By Demers Catherine   Mody Anita   Teo Koon K.   McKelvie Robert S.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 6, 2005-01 ,pp. : 351-359

Adis International

Access to resources Recommend Favorite

Ten years on: what do we know about the Gulf War syndrome?

By Wessely Simon  

Clinical Medicine, Vol. 1, Iss. 1, 2001-01 ,pp. : 28-37

Royal College Of Physicians

Access to resources Recommend Favorite